After A Dry 2013, Daiichi Sankyo Looks To Partners To Make It Rain
This article was originally published in PharmAsia News
With only one deal in the last year, Daiichi Sankyo is ready for more deal-making with a new biz dev head and the acquisitions of oncology company Plexxikon and generics play Ranbaxy well behind it.
You may also be interested in...
Amgen and Daiichi-Sankyo have entered a collaboration and license agreement for development and commercialization of Amgen's investigational bone loss therapy denosumab in Japan, the companies announced July 11
While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?
An estimated 400 million people globally are infected with hepatitis B, which can result in liver cancer and cirrhosis. Recent advances in RNA and other technologies may provide movement toward a cure, but it’s not clear yet if the biopharma industry will find the economics motivating enough for an all-out effort.